Arbutus Biopharma Corp (ABUS)

NASDAQ
Currency in USD
3.450
-0.130(-3.63%)
Closed·
After Hours
3.550+0.100(+2.899%)
·
ABUS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ABUS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.4503.565
52 wk Range
2.7054.725
Key Statistics
Edit
Prev. Close
3.58
Open
3.55
Day's Range
3.45-3.565
52 wk Range
2.705-4.725
Volume
568.25K
Average Vol. (3m)
925.41K
1-Year Change
14.01%
Book Value / Share
0.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABUS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.408
Upside
+56.76%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Arbutus Biopharma Corp News & Analysis

Show more

Arbutus Biopharma Corp Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Corp SWOT Analysis


Market Potential
Analyst targets range from $3.91 to $6.89, reflecting optimism about Arbutus's position in the competitive CHB treatment landscape
Financial Outlook
Delve into Arbutus's strategic moves to extend its financial runway into Q4 2026, balancing cost-cutting measures with ambitious clinical goals
Clinical Promise
Explore imdusiran's potential as a groundbreaking CHB therapy, with recent trials showing promising results in combination with other treatments
Hepatitis B Focus
Arbutus Biopharma narrows its focus to chronic hepatitis B treatments, particularly its lead siRNA candidate imdusiran, streamlining operations for efficiency
Read full SWOT analysis

Arbutus Biopharma Corp Earnings Call Summary for Q2/2024

  • Positive Phase 2a data for imdusiran in hepatitis B treatment; Phase 2b development planned
  • 40% workforce reduction to streamline operations and extend cash runway through Q4 2026
  • $148.5 million cash balance; sufficient to fund upcoming Phase 2b trial
  • Litigation update: trial with Moderna and Pfizer/BioNTech set for April 21, 2025
  • Considering focus on patients with baseline HBsAg levels below 1,000 for higher response rates
Last Updated: 08/01/2024, 04:48 PM
Read Full Transcript

Compare ABUS to Peers and Sector

Metrics to compare
ABUS
Peers
Sector
Relationship
P/E Ratio
−8.6x−3.0x−0.5x
PEG Ratio
−1.19−0.100.00
Price / Book
8.3x1.6x2.6x
Price / LTM Sales
103.2x3.9x3.1x
Upside (Analyst Target)
46.9%107.6%48.6%
Fair Value Upside
Unlock22.7%8.9%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.408
(+56.76% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.13 / -0.10
Revenue / Forecast
1.76M / 1.77M
EPS Revisions
Last 90 days

ABUS Income Statement

People Also Watch

10.140
ADPT
-1.46%
26.29
GSL
+0.61%
28.530
SMLR
-6.52%
68.55
ACLS
-0.60%
42.69
QFIN
+0.07%

FAQ

What Is the Arbutus Biopharma (ABUS) Stock Price Today?

The Arbutus Biopharma stock price today is 3.45

What Stock Exchange Does Arbutus Biopharma Trade On?

Arbutus Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Arbutus Biopharma?

The stock symbol for Arbutus Biopharma is "ABUS."

What Is the Arbutus Biopharma Market Cap?

As of today, Arbutus Biopharma market cap is 664.60M.

What Is Arbutus Biopharma's Earnings Per Share (TTM)?

The Arbutus Biopharma EPS (TTM) is -0.40.

When Is the Next Arbutus Biopharma Earnings Date?

Arbutus Biopharma will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is ABUS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Arbutus Biopharma Stock Split?

Arbutus Biopharma has split 0 times.

How Many Employees Does Arbutus Biopharma Have?

Arbutus Biopharma has 44 employees.

What is the current trading status of Arbutus Biopharma (ABUS)?

As of Jun 18, 2025, Arbutus Biopharma (ABUS) is trading at a price of 3.45, with a previous close of 3.58. The stock has fluctuated within a day range of 3.45 to 3.57, while its 52-week range spans from 2.71 to 4.73.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.